Nasus Pharma announced that it has signed a deal with Aptar for the use of Aptar’s Unit Dose System (UDS) nasal powder delivery device for Nasus’ NS002 (formerly FMXIN002) intranasal dry powder epinephrine product candidate through development to potential commercialization. Nasus is developing NS002 for the treatment of anaphylaxis and has previously released PK data and long-term stability data for the product.
Nasus Pharma CEO Dan Teleman commented, “This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program. Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002’s path to market while reducing development risks.”
Read the Nasus Pharma press release
